Back to search

Peptide record

TPDB19191

Antibacterial Anticancer Antiviral Hemolysis Toxicity standard
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB19191
Antibacterial Anticancer Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia dbAMP 3.0 DRAMP DRAVP 2.0 HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 9-aa standard natural multi-activity (Antibacterial, Anticancer, Antiviral, and other sources) peptide sequence curated from Peptipedia, dbAMP 3.0, DRAMP, and other sources, with an available 3D structural model.
Sequence
FLGFLKNLF
Physicochemical Analysis
C57H83N11O11
ARDCEQHIMPSTWYV
LF
1098.35
10.10
1
0
6
+1
-3.65
1.333
130.00
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
0
A
0
R
1
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
3
L
1
K
0
M
3
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 3 K: 1 M: 0 F: 3 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
9
C57H83N11O11
1098.35
10.10
+1
-3.65
1.333
Evidence Records 12 records
Evidence 1 Activity

Activity

MIC
Antibacterial
11.38 µM

Target

Staphylococcus aureus AB94004 or ATCC25923 or ATCC6538

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antibacterial
DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against S. aureus AB94004 or ATCC25923 or ATCC6538 (MIC 11.38 uM), E. coli AB94012 or ATCC25922 or DH5alpha (MIC 45.52 uM), and P. aeruginosa ATCC9027 or P
Evidence 2 Activity

Activity

MIC
Antibacterial
45.52 µM

Target

Escherichia coli AB94012 or ATCC25922 or DH5alpha

Source & Reference

DRAMP

Other

active against S. aureus AB94004 or ATCC25923 or ATCC6538 (MIC 11.38 uM), E. coli AB94012 or ATCC25922 or DH5alpha (MIC 45.52 uM), and P. aeruginosa ATCC9027 or PAO1 (MIC 45.52-91.04 uM). Virus: inhibits hepatitis C vir
Evidence 3 Activity

Activity

MIC
Antibacterial
45.52-91.04 µM

Target

Pseudomonas aeruginosa ATCC9027 or PAO1

Source & Reference

DRAMP

Other

or ATCC6538 (MIC 11.38 uM), E. coli AB94012 or ATCC25922 or DH5alpha (MIC 45.52 uM), and P. aeruginosa ATCC9027 or PAO1 (MIC 45.52-91.04 uM). Virus: inhibits hepatitis C virus (HCV) infection (EC50 1.84 ug/ml).
Evidence 4 Activity

Activity

MIC
Antiviral
11.38 µM

Target

Staphylococcus aureus AB94004 or ATCC25923 or ATCC6538

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
dbAMP 3.0 classified under the Anti-viral function class. DRAMP antiviral activity supported by activity records against viral targets.
active against S. aureus AB94004 or ATCC25923 or ATCC6538 (MIC 11.38 uM), E. coli AB94012 or ATCC25922 or DH5alpha (MIC 45.52 uM), and P. aeruginosa ATCC9027 or P
Evidence 5 Activity

Activity

MIC
Antiviral
45.52 µM

Target

Escherichia coli AB94012 or ATCC25922 or DH5alpha

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

active against S. aureus AB94004 or ATCC25923 or ATCC6538 (MIC 11.38 uM), E. coli AB94012 or ATCC25922 or DH5alpha (MIC 45.52 uM), and P. aeruginosa ATCC9027 or PAO1 (MIC 45.52-91.04 uM). Virus: inhibits hepatitis C vir
Evidence 6 Activity

Activity

MIC
Antiviral
45.52-91.04 µM

Target

Pseudomonas aeruginosa ATCC9027 or PAO1

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

or ATCC6538 (MIC 11.38 uM), E. coli AB94012 or ATCC25922 or DH5alpha (MIC 45.52 uM), and P. aeruginosa ATCC9027 or PAO1 (MIC 45.52-91.04 uM). Virus: inhibits hepatitis C virus (HCV) infection (EC50 1.84 ug/ml).
Evidence 7 Activity

Activity

HC50
Hemolysis
137.9 µg/mL
[Ref.23415044] HC50 = 137.9 µg/ml against human red blood cells.

Target

human red blood cells

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
Biomaterials. 2013 Apr 34(13):3511-22.

Other

Source Activity Label Source Definition
Hemolysis
Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 8 Activity

Activity

50% Hemolysis
Toxicity
137.9 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 137.9 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. | Biomaterials | 2013
Evidence 9 Activity

Activity

5% Hemolysis
Toxicity
50 µg/mL
Hemolytic Cytotoxic
5% Hemolysis | 50 | µg/mL | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity of CT-K3K7, a modified peptide by lysine substitutions from ctry2459 - A Chaerilus tryznai scorpion venom peptide | Toxicon | 2022
Evidence 10 Activity

Activity

70% Hemolysis
Toxicity
200 µg/mL
Hemolytic Cytotoxic
70% Hemolysis | 200 | µg/mL | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activity of CT-K3K7, a modified peptide by lysine substitutions from ctry2459 - A Chaerilus tryznai scorpion venom peptide | Toxicon | 2022
Evidence 11 Activity

Activity

HC50
Toxicity
137.9 µg/mL
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.23415044] HC50 = 137.9 µg/ml against human red blood cells. | Cytotoxicity: [Ref.23415044] CC50=79.8 µg/ml against Huh7.5.1 cells.

Target

erythrocytes

Source & Reference

NA
DRAMP
Biomaterials. 2013 Apr 34(13):3511-22.
Evidence 12 Hemolysis

Activity

137.9 µg/mL
HC50
[Ref.23415044] HC50 = 137.9 µg/ml against human red blood cells.
Hemolysis

Target

human red blood cells

Source & Reference

HemoPI PD_Hemolysis
Biomaterials. 2013 Apr 34(13):3511-22.
DRAMP4
PD_Hemolysis